コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 se through the LANCL2-mediated activation of adenylate cyclase.
2 omyocyte proliferation through inhibition of adenylate cyclase.
3 TX effector domain is a catalytically active adenylate cyclase.
4 kinase A by a bicarbonate-dependent soluble adenylate cyclase.
5 pression of genes such as cAMP receptors and adenylate cyclase.
6 (i)-mediated effects including inhibition of adenylate cyclase.
7 1 Ser845 than when PKA is anchored away from adenylate cyclase.
8 ent of an anthrax toxin that functions as an adenylate cyclase.
9 , inhibits forskolin-mediated stimulation of adenylate cyclase.
10 perform uncoupled respiration downstream of adenylate cyclase.
11 r signal-regulated kinases and inhibition of adenylate cyclase.
12 ansduction from beta-adrenergic receptors to adenylate cyclase.
13 d was rescued by pharmacological blockade of adenylate cyclase.
14 The present study investigates the role of adenylate cyclase 1 (AC1) in developmental refinement of
17 ice carrying a targeted null mutation of the adenylate cyclase 1 gene (AC1-KO) and wild-type litterma
20 ing such as Galpha(i2) protein (Galpha(i2)), adenylate cyclase 3 (Adcy3), protein expression of tumor
22 hisms (SNPs) within the ADCY5 gene, encoding adenylate cyclase 5, are associated with elevated fastin
24 a previously unrecognized connection between adenylate cyclase 6 (AC6), a cilia signaling mediator, a
26 kinase 2 (JAK2)/STAT5 cascade, up-regulated adenylate cyclase 6 (AC6), increased cAMP, enhanced JNK1
28 ancer: stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated k
29 th identified conserved human-mouse changes, adenylate cyclase 7 (ADCY7), on threat-associated amygda
30 orphisms in the human adenylate cyclase gene adenylate cyclase 8 (ADCY8) that correlate with glioma r
31 ociated with known (TSHR, GNAS) or presumed (adenylate cyclase 9 [ADCY9]) alterations in cAMP pathway
35 ry cascade consisting of three receptor-like adenylate cyclases, a Crp-like regulator, and a target g
37 selectivity of the three most commonly used adenylate cyclase (AC) inhibitors in a battery of cell l
40 vate phosphotransferase system (PEP-PTS) and adenylate cyclase (AC) IV (encoded by BB0723 [cyaB]) are
44 ular matrix protein laminin (LMN), decreases adenylate cyclase (AC)/cAMP and increases beta(2)-adrene
46 fly brains and transgenic RNAi, we show that adenylate cyclase AC3 underlies PDF signaling in M cells
47 olfactory receptors (ORs), olfactory-related adenylate cyclase (AC3) and the olfactory G protein (G(o
48 jected with small interfering RNA for type 7 adenylate cyclase (AC7), with or without VIP treatment.
49 which still occurred in mutants lacking the adenylate cyclases ACG or ACR, or the cAMP phosphodieste
51 at targeted both GPCR signaling pathways and adenylate cyclases (ACs) improved photoreceptor cell sur
52 denylate cyclase, the neuropeptide Pituitary Adenylate Cyclase Activating Peptide (PACAP) impacts lev
53 ons and hippocampal autapses using pituitary adenylate cyclase activating peptide (PACAP) to induce n
54 PVN injections of the neuropeptide pituitary adenylate cyclase activating peptide (PACAP38) enhance S
55 ompression, with ADCYAP1 (encoding pituitary adenylate cyclase activating peptide, PACAP) being the m
56 tment or agonist (isoproterenol or pituitary adenylate cyclase activating peptide-27) stimulation of
57 S) has been shown to increase BNST pituitary adenylate cyclase activating polypeptide (PACAP) and its
58 recent evidence has suggested that pituitary adenylate cyclase activating polypeptide (PACAP) has cri
62 rphism in the PACAP receptor gene ADCYAP1R1, adenylate cyclase activating polypeptide 1 receptor type
63 tionarily conserved neuropeptides, including adenylate cyclase activating polypeptide 1b (adcyap1b),
64 ave reported that the neuropeptide pituitary adenylate cyclase activating polypeptide 38 (PACAP38) al
65 he type I receptor (PAC1-R) of the pituitary adenylate cyclase activating polypeptide has been report
66 the effects of blocking glutamate, pituitary adenylate cyclase activating polypeptide, and microglia
67 Chemicals, such as glutamate and pituitary adenylate cyclase activating polypeptide, whose expressi
68 e counterpart, human RPS23RG1 interacts with adenylate cyclase, activating PKA/CREB, and inhibiting G
69 ctive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) and their c
71 ssociation studies have implicated pituitary adenylate cyclase-activating peptide (PACAP) systems in
73 tive intestinal peptide (VIP), and pituitary adenylate cyclase-activating peptide (PACAP) which contr
76 It is regulated by neural (e.g., pituitary adenylate cyclase-activating peptide), hormonal (e.g., g
77 structures of peptide and Gs-bound pituitary adenylate cyclase-activating peptide, PAC1 receptor, and
78 endocrine cell neuritogenesis, and pituitary adenylate cyclase-activating polypeptide (PACAP) activat
81 found higher circulating levels of pituitary adenylate cyclase-activating polypeptide (PACAP) associa
82 ucagon family of related peptides, pituitary adenylate cyclase-activating polypeptide (PACAP) binding
90 at intracerebral administration of pituitary adenylate cyclase-activating polypeptide (PACAP), an end
91 such brain stress response system, pituitary adenylate cyclase-activating polypeptide (PACAP), and it
92 olypeptide type I receptor (PAC1), pituitary adenylate cyclase-activating polypeptide (PACAP)-38, or
95 Growing evidence suggests that the pituitary adenylate cyclase-activating polypeptide (PACAP)/PAC1 re
96 tropin-releasing hormone (TRH) and pituitary adenylate cyclase-activating polypeptide (PACAP, also kn
100 to other neuritogenic treatments (pituitary adenylate cyclase-activating polypeptide and 12-O-tetrad
101 erve growth factor, or addition of pituitary adenylate cyclase-activating polypeptide had no effect o
103 with the endogenous agonist of the pituitary adenylate cyclase-activating polypeptide type I receptor
104 The neurotrophic peptide PACAP (pituitary adenylate cyclase-activating polypeptide) elevates cAMP
105 r corticotrophin-releasing factor, pituitary adenylate cyclase-activating polypeptide, and gastric in
106 stromal-derived factor-1alpha, and pituitary adenylate cyclase-activating polypeptide, which may impr
107 rapeutic potential of neuropeptide pituitary adenylate cyclase-activating polypeptides (PACAP) in a m
108 protein-coupled receptor ligands, pituitary adenylate cyclase-activating protein (20 pmol/L, >8-fold
109 m these progenitors transform in response to adenylate cyclase activation from being UCP1 negative to
114 cked by alpha2 antagonists, cAMP analogs, an adenylate cyclase activator, and a cAMP-specific phospho
115 enosine monophosphate (cAMP) analogue, or an adenylate cyclase activator, indicating that nimodipine
116 tion of synaptic transmission induced by the adenylate-cyclase activator forskolin in cultured cortic
117 agents, melanocortin 1 receptor activators, adenylate cyclase activators, phosphodiesterase 4D3 inhi
118 of cAMP on Fe(II) and 5hmC was confirmed by adenylate cyclase activators, phosphodiesterase inhibito
119 Biological assays for binding affinities and adenylate cyclase activities for the hMC1R, hMC3R, hMC4R
121 tion with native PA and an EF mutant lacking adenylate cyclase activity (EF-K346R) failed to enhance
122 acis edema factor (EF) mutant having reduced adenylate cyclase activity (i.e., EF-S414N) enhances ant
123 ular matrix protein, laminin (LMN) decreases adenylate cyclase activity and beta(1)-adrenergic recept
124 the valence in DRD mice with an increase in adenylate cyclase activity and blunted behavioural respo
125 reduces aquaporin 2 expression by modulating adenylate cyclase activity and cAMP generation, thereby
126 handling, upregulating beta(1) receptors and adenylate cyclase activity and suppressing G(i)-coupled
127 eceptors acts via FAK/PI-(3)K/Akt to inhibit adenylate cyclase activity and thereby down-regulates be
128 marily couples to G(i/o) proteins to inhibit adenylate cyclase activity and typically induces downstr
129 mary, a fully functional PA and a minimum of adenylate cyclase activity are needed for EdTx to act as
131 tion results via bidirectional modulation of adenylate cyclase activity in presynaptic glutamatergic
132 (a putative cyaB homolog) was shown to have adenylate cyclase activity in vitro; however, mutants wi
137 pression of cAMP production by inhibition of adenylate cyclase activity or augmentation of cAMP degra
139 ugs inhibited 10 microM forskolin-stimulated adenylate cyclase activity with potencies similar to the
140 , D1-dopamine receptors were supersensitive; adenylate cyclase activity, locomotor activity and stere
141 nal processes, such as protein synthesis and adenylate cyclase activity, through protein-protein inte
142 e melanocortin receptor type 1 and activated adenylate cyclase activity, which in turn activated Xero
147 that knocking down the calmodulin-activated adenylate cyclase ADCY8 makes retinal axons insensitive
148 ption through a calcium-dependent isoform of adenylate cyclase, ADCY8, and the transcription factor,
149 ns in Caenorhabditis elegans, the engineered adenylate cyclase affected worm behavior in a light-depe
151 mechanism is mediated through activation of adenylate cyclase and an increase of cAMP and intracellu
153 proteins and ultimately in the activation of adenylate cyclase and cyclic AMP (cAMP) production.
154 n the distal renal tubule), possibly through adenylate cyclase and cyclic AMP signaling and a cytopla
155 cAMP-dependent signaling occurs upstream of adenylate cyclase and downstream of receptor activation.
157 hese findings suggest that Fsk activation of adenylate cyclase and PKA can negatively regulate IL-2 s
158 a synthetic OR14I1 peptide and inhibitors of adenylate cyclase and protein kinase A (PKA) signaling.
160 a(1) signalling is due to down-regulation of adenylate cyclase and to gain insight into the signallin
161 n the constitutive activation of Gsalpha and adenylate cyclase and to lead to the autonomous synthesi
162 -MSH))-induced increase in the activities of adenylate cyclase and tyrosinase, the rate-limiting enzy
163 imimetics promote CFTR opening by activating adenylate cyclase and we show that Ca(2+)-stimulated typ
164 ve evolution to accommodate the emergence of adenylate cyclases and thus the signaling molecule 3',5'
165 Transcriptome analysis of cyaA (encoding adenylate cyclase) and crp (encoding cAMP receptor prote
166 a-Melanocortin and forskolin, which activate adenylate cyclase, and 12-O-tetradecanoylphorbol-13-acet
167 types via a pathway involving G G proteins, adenylate cyclase, and cAMP-dependent protein kinase.
168 -specific phosphodiesterases, cyanobacterial adenylate cyclases, and formate hydrogen lyase transcrip
169 reported structures of mRNA capping enzymes, adenylate cyclases, and polyphosphate polymerases sugges
171 , we developed a highly efficient detoxified adenylate cyclase-based vector (CyaA) capable of deliver
172 contrast, mGluR3, whose activation inhibits adenylate cyclase but not calcium signaling, was express
175 pends on the G(alpha) subunit via a G(alpha)-adenylate cyclase-cAMP cascade and requires participatio
176 he specific inhibitory action of GnIH on the adenylate cyclase/cAMP/protein kinase A pathway, suggest
177 8 integrin and on delivery of its N-terminal adenylate cyclase catalytic domain (AC domain) into the
181 on assay as well as the calmodulin-dependent adenylate cyclase (CyaA) assay in the surrogate host L.
183 as restricted in its ability to inject a T3E-adenylate cyclase (CyaA) injection reporter into PTI-ind
188 cies was less able to activate its effector, adenylate cyclase (Cyr1), unless tethered to the membran
190 ivation of A1 receptors causes inhibition of adenylate cyclase, decreases in intracellular cyclic AMP
191 sion seen upon deletion of the gene encoding adenylate cyclase (Deltacya) was reversed by supplementa
192 tethered APP intracellular domain results in adenylate cyclase-dependent activation of PKA (protein k
194 Forskolin, which like AlF(4)(-) activates adenylate cyclase, did not redistribute perilipin 3, but
197 hracis virulence factors and consists of the adenylate cyclase edema factor (EF) and protective antig
198 imulations show that PKA colocalization with adenylate cyclase, either in the spine head or in the de
201 Furthermore, we demonstrate that the Rv0386 adenylate cyclase facilitates delivery of bacterial-deri
202 f a GAF (cGMP-stimulated phosphodiesterases, adenylate cyclases, FhlA) domain that binds BCAAs and a
204 n of the amino acid sequences of globins and adenylate cyclase from prokaryotic to eukaryotic organis
205 its stalk by expression of a light-activated adenylate cyclase from the ACA promoter and exposure to
207 we report genetic polymorphisms in the human adenylate cyclase gene adenylate cyclase 8 (ADCY8) that
210 pac-independent signaling pathway: PACAP --> adenylate cyclase --> cAMP --> ERK --> neuritogenesis ha
211 nd the G protein-coupled receptor --> Gs --> adenylate cyclase --> cAMP --> neuritogenic cAMP sensor-
212 om the G protein-coupled receptor --> Gs --> adenylate cyclase --> cAMP --> PKA --> cAMP response ele
213 e we report a globin-coupled heme containing adenylate cyclase (HemAC-Lm) in the unicellular eukaryot
214 y encode TFP, the Chp system, FimL, FimV and adenylate cyclase homologs, suggesting that surface sens
216 er blocking PI3K, could be suppressed by the adenylate cyclase III (ACIII) blockers MDL12330A (cis-N-
217 trafficking of olfactory signaling proteins, adenylate cyclase III (ACIII), and cyclic nucleotide-gat
219 , as we were unable to identify a functional adenylate cyclase in S. aureus and only detected 2',3'-c
220 nteracted with the RAS-binding domain of the adenylate cyclase in vitro, and the cAMP analogue 8-brom
221 )AR than 2-H and 2-F, functional efficacy in adenylate cyclase inhibition varied, and introduction of
222 se effects are reduced in the presence of an adenylate cyclase inhibitor, yet persist in the presence
223 zed by pretreatment with protein kinase A or adenylate cyclase inhibitors, H89 and di-deoxyadenosine,
225 se and we show that Ca(2+)-stimulated type I adenylate cyclase is expressed in the developing human l
226 clarify how O2-dependent cAMP generation by adenylate cyclase is likely to function in cellular adap
229 The findings suggest ADCY7 is probably the adenylate cyclase isoform most relevant to PACAP's actio
231 , and demonstrate that Galpha(S) coupling to adenylate cyclase mediates membrane-tethered APP intrace
232 ase of intracellular cAMP by an activator of adenylate cyclase or an analog of cAMP, or a blockade of
233 ellular cAMP and activate PKA (activators of adenylate cyclase or inhibitors of phosphodiesterase 4)
234 bromo-cyclic AMP; 8-Br-cAMP), stimulation of adenylate cyclase, or prostanoids known to drive cAMP re
235 ng RNA approaches, a PGE2/E prostanoid (EP)2/adenylate cyclase pathway was implicated in these suppre
238 with epithelial tropism and the role of the adenylate cyclase/PKA/AKT-mediated signaling pathway in
240 satility, naturally occurring photoactivated adenylate cyclases promote the synthesis of the second m
241 f AMP and related nucleotides, which inhibit adenylate cyclase, reduce levels of cyclic AMP and prote
242 re, we tested this hypothesis by engineering adenylate cyclases regulated by light in the near-infrar
244 lmonella effector proteins were fused to the adenylate cyclase reporter (CyaA'), and each of them was
247 d to encode class I, class IV, and class III adenylate cyclases, respectively, have been identified i
249 ough a mechanism involving somatic Galpha(s)-adenylate cyclase signaling and soma-to-germline gap-jun
250 ally large when MSP is present and Galpha(s)-adenylate cyclase signaling in the gonadal sheath cells
251 and cytoplasmic streaming require Galpha(s)-adenylate cyclase signaling in the gonadal sheath cells,
252 ion events in the germline require Galpha(s)-adenylate cyclase signaling in the gonadal sheath cells.
253 sent genetic evidence that MSP and Galpha(s)-adenylate cyclase signaling regulate oocyte growth and m
255 we show that the major effector of Galpha(s)-adenylate cyclase signaling, protein kinase A (PKA), is
256 y develop alternative strategies to activate adenylate cyclase signalling in multiple cancer types.
257 N'-tetraacetic acid-acetoxymethyl ester, the adenylate cyclase stimulant forskolin, and a specific pr
259 ical concerns by expressing a photoactivated adenylate cyclase that allows light-sensitive control of
261 a factor, the catalytic subunit of ET, is an adenylate cyclase that impairs host defenses by raising
262 It produces edema toxin (EdTx), a powerful adenylate cyclase that increases cyclic AMP (cAMP) level
263 sting that Galpha(z) is a tonic inhibitor of adenylate cyclase, the enzyme responsible for the conver
265 ensitive transcription (git) genes, encoding adenylate cyclase, the PKA catalytic subunit, and seven
266 ogous G-protein alpha subunits that activate adenylate cyclase, thereby serving as crucial mediators
267 ransmembrane communication by activating the adenylate cyclase through the N-terminal region of both
269 enetic strategy that uses a photoactivatable adenylate cyclase to achieve real-time regulation of cAM
273 with Bordetella pertussis, and the secreted adenylate cyclase toxin (ACT) is essential for the bacte
276 B. pertussis uses pertussis toxin (PT) and adenylate cyclase toxin (ACT) to kill and modulate host
277 The catalytic domain of Bordetella pertussis adenylate cyclase toxin (ACT) translocates directly acro
278 ertussis and B. bronchiseptica, which encode adenylate cyclase toxin (ACT), are functionally intercha
280 l toxins, including pertussis toxin (PT) and adenylate cyclase toxin (ACT), which have both been show
281 ent of whooping cough, secretes and releases adenylate cyclase toxin (ACT), which is a protein bacter
282 everal virulence factors, among which is the adenylate cyclase toxin (CyaA) that plays a crucial role
284 overn the activities of Bordetella pertussis adenylate cyclase toxin (CyaA), Escherichia coli alpha-h
285 analysis showed that cyaA, the gene encoding adenylate cyclase toxin (CyaA), was the most downregulat
286 ding domain (RD) of the Bordetella pertussis adenylate cyclase toxin CyaA fused to the C terminus of
287 This allowed the engineering of recombinant adenylate cyclase toxin from Bordetella pertussis for th
288 ine with the finding that antibodies against adenylate cyclase toxin were only elicited by BPZE1.CONC
289 t advances in understanding the functions of adenylate cyclase toxin, a type 1 secretion system (T1SS
295 ction was confirmed using beta-lactamase and adenylate cyclase translocation assays, and a C-terminal
297 ta1AR signal transduction cascade, including adenylate cyclase VI and the catalytic subunit of the cA
298 d inwardly rectifying potassium channels and adenylate cyclase, were not modulated by GPR18 signaling
299 lly inhibited 10 microM forskolin-stimulated adenylate cyclase, whereas the other drugs produced part
300 nesis of one of these fusions resulted in an adenylate cyclase with a sixfold photodynamic range.